Previous 10 | Next 10 |
2024-04-22 10:01:12 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Tech advances are catalyzing the Health Care sector with improved ...
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a...
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., ...
2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero ( MNY ) +5% . Losers: Ocular Therapeutix...
2024-03-25 16:35:19 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalizat...
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American Colle...
2024-03-12 11:38:13 ET Read the full article on Seeking Alpha For further details see: Lexicon stock slides 8% after rallying 30% in prior session
THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients...
2024-03-12 03:57:11 ET Summary Lexicon Pharmaceuticals is actively working to create shareholder value by pursuing new indications for the lead drug sotagliflozin. The company reported $0.7 million in Inpefa sales for Q4 2023, below expectations, but these are still early days for...
2024-03-11 16:51:09 ET More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value Lexicon Pharmaceuticals: Navigatin...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Jeff...
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon’s president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon ...
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...